Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Three Million a Year Die From Tobacco-Related Causes

August 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

BETHESDA, Md--Although there is some "good news" on the tobacco front--lung cancer deaths have declined in one US demographic group--the bad news continues to pour in from all over the globe, an NCI official told a symposium sponsored by NCI and the American Society of Clinical Oncology (ASCO).

BETHESDA, Md--Although there is some "good news" onthe tobacco front--lung cancer deaths have declined in one USdemographic group--the bad news continues to pour in from allover the globe, an NCI official told a symposium sponsored byNCI and the American Society of Clinical Oncology (ASCO).

"One of every 10 people now alive today will die of tobacco-relateddisease unless serious action is taken on a worldwide scale,"said Thomas J. Glynn, PhD, chief of the Prevention and ControlExtramural Research Branch in the Division of Cancer Preventionand Control.

Worldwide, he said, two tobacco companies--R.J. Reynolds and PhilipMorris--have increased sales by almost 200 billion cigarettesper year, primarily because of sales in Eastern Europe and developingcountries. China, with 23% of the world's population, has about29% of the world's smokers.

Dr. Glynn cited WHO estimates that about 3 million people peryear are dying from tobacco-related disease throughout the world."Without a concerted worldwide effort, this will rise toabout 10 million per year by the year 2020," he said.

For 1995, he said, this works out roughly to six deaths everyminute from tobacco use--one person in the European Union, onein the United States, one in the former USSR, one in the otherdeveloped nations, one in China, and one in the developing nations.

Wasn't There Some Good News?

Even though lung cancer rates continue to rise in the United States,"we're starting to see the first decline over the past 5years or so" in at least one major demographic group--45-to-54-year-old white males," Dr. Glynn said. "This isamong the group that has stopped smoking in the past 2 decades."

Indeed, about 40 million US adults, or nearly half of all livingadults, have quit smoking. "So, in a sense, Senator [Robert]Dole is absolutely correct: you can quit smoking," Dr. Glynnsaid, referring to the Republican presidential candidate's statementthat only some smokers become addicted to tobacco while otherscan "take it or leave it." But for most people, Dr.Glynn pointed out, "quitting is very difficult, and nicotineis most certainly addictive for everyone."

The bad news for the United States, Dr. Glynn said, is that adolescentsmokers are replacing the adult smokers who quit or die in aboutequal numbers. Furthermore, sales of smokeless (chewing) tobacco,used almost exclusively among males, are showing "sharp increases."

Dr. Glynn stressed that the benefits of quitting are well worthit. After 10 years' abstinence, the risk of lung cancer is cut30% to 50%. Oral cancer risk is about half after 5 years' cessation."The same for bladder cancer," Dr. Glynn said. After5 years' abstinence, the risk of "premature death" frombladder cancer is reduced by about 50%, and after 15 years, thereis about a 90% risk reduction.

Helping Patients Quit

Physicians can help their patients realize the benefits of quittingsmoking by taking four easy steps with each patient:

The NCI booklet "How to Help Your Patients Stop Smoking"can be obtained by calling the NCI's Cancer Information Serviceat 1-800-4-CANCER.

Articles in this issue

Chemo Improves Pain Relief in Advanced Prostate Cancer
Multimedia Computer Program Patiently Answers Young Cancer Patients' Questions
NCCR Urges Congress to Support Senate Bill for Cancer Research
Researchers Propose New Treatment Guidelines for HIV
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Anderson
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samples
New Thinking on HIV Progression Leads to New Strategies
Hospitals Told Not to Capitate for 'Wrong' Reasons
More Study Needed of Possible Carcinogenesis of Winter Gas Additive
President Makes NCAB Appointments
Algorithm Identifies Women at Risk of Ovarian Cancer
Three Million a Year Die From Tobacco-Related Causes
Marketing of Cancer Services Must Include All Payer Modalities
Dr. Kessler Corrects Misapprehension That The FDA Cannot Regulate Tobacco Products
New Surgical Techniques May Reduce Impotence, Incontinence
Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content
Advertisement

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Related Content
Advertisement

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.